Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
214
datasets available to search
ShareScore release 0.9.0
Dataset results
214 results for “Pleural mesothelioma”
Dataset related to article "Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma "
<p>This record contains raw data related to article “Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma"</p> <p><strong>Objectives: </strong> We examined a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent surgery in our institution during the last 20 years. Across this period, we changed our surgical approach to MPM, adopting extended pleurectomy and decortication (eP/D) instead of extrapleural pneumonectomy (EPP). In this study, we compare the perioperative outcomes and long-term survival of patients who underwent EPP vs. eP/D.</p> <p><strong>Methods: </strong> A retrospective analysis was carried out of all the MPM patients identified from our departmental database who underwent EPP or P/D from 2000 to 2021. Clavien-Dindo criteria was adopted to score postoperative complications, while Kaplan-Meier methods and a Cox multivariable analysis were used to perform the survival analysis.</p> <p><strong>Results: </strong> Of 163 patients, 78 (48%) underwent EPP and 85 (52%) eP/D. Induction chemotherapy was significantly administrated more often in the eP/D group (88% vs. 51%). Complete trimodality treatment including induction chemotherapy, radical surgery, and adjuvant radiotherapy was administered in 74% of the eP/D group versus 32% of the EPP group (<em>p</em> &lt; 0.001). The postoperative morbidity rate was higher in the eP/D group (54%) compared to the EPP group (36%) (<em>p</em> = 0.02); no statistically significant differences were identified concerning major complications (EPP 43% vs. eP/D 24%, <em>p</em> = 0.08). No statistical differences were identified in 30-day mortality, 90-day mortality, median disease-free, and overall survival statistics between the two groups. The Cox multivariable analysis confirmed no induction chemotherapy (HR, 0.5; <em>p</em> = 0.002), RDW (HR, 1.08; <em>p</em> = 0.02), and the presence of pathological nodal disease (HR, 1.99; <em>p</em> = 0.001) as factors associated with worse survival in the entire series.</p> <p><strong>Conclusions: </strong> Our data support that eP/D is a well-tolerated procedure allowing the implementation of a trimodality strategy (induction chemotherapy, surgery, and radiotherapy) in most MPM patients. When eP/D is offered in this setting, the oncological results are comparable to EPP. To obtain the best oncological results, the goal of surgical resection should be macroscopic complete resection (R0) in carefully selected patients (clinical N0).</p>
Dataset related to article "Important functional role of the protein Osteopontin in the progression of malignant pleural mesothelioma"
<p>This record contains raw data related to article “Important functional role of the protein Osteopontin in the progression of malignant pleural mesothelioma"</p> <p>Background: Malignant Pleural Mesothelioma (MPM) is an aggressive cancer of the mesothelial lining associated with exposure to airborne non-degradable asbestos fibers. Its poor response to currently available treatments prompted us to explore the biological mechanisms involved in its progression. MPM is characterized by chronic non-resolving inflammation. in this study we investigated which inflammatory mediators are mostly expressed in biological tumour samples from MPM patients.<br> Methods: Expression and quantification of Osteopontin (OPN) was detected in tumour and plasma samples of MPM patients by mRNA, immunohistochemistry and ELISA. The functional role of OPN was investigated in mouse MPM cell lines in vivo using an orthotopic syngeneic mouse model.<br> Results: In patients with MPM, the protein OPN was significantly more expressed in tumours than in normal pleural tissues and predominantly produced by mesothelioma cells; plasma levels were elevated in patients and associated with poor prognosis. However, modulation of OPN levels was not significantly different in a series of 18 MPM patients receiving immunotherapy with durvalumab alone or with pembrolizumab in combination with chemotherapy, some of whom achieved a partial clinical response. Two established murine mesothelioma cell lines: AB1 and AB22 of sarcomatoid and epithelioid histology, respectively, spontaneously produced high levels of OPN. Silencing of the OPN gene (Spp1) dramatically inhibited tumour growth in vivo in an orthotopic model, indicating that OPN has an important promoting role in the proliferation of MPM cells. Treatment of mice with anti-CD44 mAb, blocking a major OPN receptor, significantly reduced tumour growth in vivo.<br> Conclusions: These results demonstrate that OPN is an endogenous growth factor for mesothelial cells and inhibition of its signaling may be helpful to restrain tumour progression in vivo. These findings have translational potential to improve the therapeutic response of human MPM</p>
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT01353482. IPD Sharing: Not stated. Countries: 0. Publications: 0.
DNA methylation-based machine learning classification distinguishes pleural mesothelioma from chronic pleuritis, pleural carcinosis, and pleomorphic lung carcinomas
GEO Series GSE203061. Homo sapiens. 76 samples. Type: Methylation profiling by genome tiling array.
Pharmacogenomic characterisation of a large collection of primary cell lines identifies novel therapeutic options for pleural mesothelioma
GEO Series GSE279871. Homo sapiens. 62 samples. Type: Methylation profiling by genome tiling array.
Copy number variations analysis by CytoscanHD array of 33 human pleural mesothelioma cell lines
GEO Series GSE134349. Homo sapiens. 33 samples. Type: Genome variation profiling by SNP array.
Affymetrix OncoScan FFPE Microarray data for Malignant Pleural Mesothelioma Samples
GEO Series GSE109305. Homo sapiens. 4 samples. Type: Genome variation profiling by SNP array.
Mithramycin Depletes Sp1 and Activates p53 to Mediate Senescence and Apoptosis of Pleural Mesothelioma Cells
GEO Series GSE64738. Homo sapiens. 45 samples. Type: Expression profiling by array.
Identification of novel markers for malignant pleural mesothelioma diagnosis
GEO Series GSE17310. Homo sapiens. 54 samples. Type: Expression profiling by array.
Dataset related to article "In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma."
<p>OBJECTIVES:</p> <p>In-vivo characterization of malignant pleural mesothelioma (MPM) with C-methionine PET/computed tomography (MET PET).</p> <p>METHODS:</p> <p>Between September 2014 and February 2016, 30 consecutive patients with clinical suspicion of MPM were prospectively recruited. The study was approved and registered at www.clinicaltrials.gov (<a href="http://clinicaltrials.gov/show/NCT02519049">NCT02519049</a>). Patients were evaluated at baseline with MET PET (experimental) and fluorine-18 fluorodeoxyglucose PET/computed tomography (FDG PET) (standard). Principal parameters analyzed were SUVmax, SUVmean, metabolic tumor volume (MTV), and metabolic tumor burden (MTB  =&thinsp;MTV ×SUVmean). The reference standard for diagnostic performance was based on histology.</p> <p>RESULTS:</p> <p>The presence of malignancy was confirmed in 29/30 patients: 23 (76.6%) with MPM (20 epithelioid, two biphasic, and one sarcomatoid), five (16.6%) with adenocarcinoma of the lung, and one (3.3%) with an undifferentiated carcinoma. In one case, diagnosis was benign pleural inflammation. All tumors showed increased uptake of C-methionine: median SUVmax, SUVmean, MTV, and MTB were, respectively, 5.70 [95% confidence interval (CI): 4.51-6.79], 3.15 (95% CI: 2.71-3.40), 33.85 (95% CI: 14.08-66.64), and 105.25 (95% CI: 41.77-215.25). Pathology data revealed MTV and MTB to be significantly higher in nonepithelioid histology (P < 0.05). The other parameters showed a homogeneous distribution across the tumor types. Overall, MET PET identified 49 lymph nodes, compared with 34 nodes on FDG PET, demonstrating a sensitivity of 91% (95% CI: 80-96%), a positive predictive value of 92% (95% CI: 82- 97%), and an accuracy of 85% (P = 0.0042).</p> <p>CONCLUSIONS:</p> <p>MET PET is able to characterize MPM lesions regardless of histology. This technique shows higher sensitivity than FDG PET for the identification of secondary lymph nodes.</p>
Dataset related to article "Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study"
<p>This record contains data related to article “Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study”.</p> <p>The abstract is not yet available.</p> <p> </p>
Dataset related to article "Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma"
<p>This record contains raw data related to article "Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma"</p><p><strong>Background: </strong>Malignant Pleural Mesothelioma (MPM) is an aggressive cancer of the mesothelial lining associated with exposure to airborne non-degradable asbestos fibers. Its poor response to currently available treatments prompted us to explore the biological mechanisms involved in its progression. MPM is characterized by chronic non-resolving inflammation; in this study we investigated which inflammatory mediators are mostly expressed in biological tumor samples from MPM patients, with a focus on inflammatory cytokines, chemokines and matrix components.</p><p><strong>Methods: </strong>Expression and quantification of Osteopontin (OPN) was detected in tumor and plasma samples of MPM patients by mRNA, immunohistochemistry and ELISA. The functional role of OPN was investigated in mouse MPM cell lines <i>in vivo</i> using an orthotopic syngeneic mouse model.</p><p><strong>Results: </strong>In patients with MPM, the protein OPN was significantly more expressed in tumors than in normal pleural tissues and predominantly produced by mesothelioma cells; plasma levels were elevated in patients and associated with poor prognosis. However, modulation of OPN levels was not significantly different in a series of 18 MPM patients receiving immunotherapy with durvalumab alone or with pembrolizumab in combination with chemotherapy, some of whom achieved a partial clinical response. Two established murine mesothelioma cell lines: AB1 and AB22 of sarcomatoid and epithelioid histology, respectively, spontaneously produced high levels of OPN. Silencing of the OPN gene (<i>Spp1</i>) dramatically inhibited tumor growth <i>in vivo</i> in an orthotopic model, indicating that OPN has an important promoting role in the proliferation of MPM cells. Treatment of mice with anti-CD44 mAb, blocking a major OPN receptor, significantly reduced tumor growth <i>in vivo</i>.</p><p><strong>Conclusion: </strong>These results demonstrate that OPN is an endogenous growth factor for mesothelial cells and inhibition of its signaling may be helpful to restrain tumor progression <i>in vivo</i>. These findings have translational potential to improve the therapeutic response of human MPM.</p>
MesoHET (Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma)
GEO Series GSE175769. Homo sapiens. 10 samples. Type: Methylation profiling by genome tiling array.
Expression data from in vitro healthy cells and malignant pleural mesothelioma cell lines infected by oncolytic attenuated measles virus or treated by exogenous type I interferon
GEO Series GSE117668. Homo sapiens. 48 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.